RT Journal Article
T1 Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
A1 Neukam, Karin
A1 Munteanu, Daniela I
A1 Rivero-Juárez, Antonio
A1 Lutz, Thomas
A1 Fehr, Jan
A1 Mandorfer, Mattias
A1 Bhagani, Sanjay
A1 López-Cortés, Luis F
A1 Haberl, Annette
A1 Stoeckle, Marcel
A1 Márquez, Manuel
A1 Scholten, Stefan
A1 de Los Santos-Gil, Ignacio
A1 Mauss, Stefan
A1 Rivero, Antonio
A1 Collado, Antonio
A1 Delgado, Marcial
A1 Rockstroh, Juergen K
A1 Pineda, Juan A
K1 Coinfección
K1 Europa
K1 Femenino
K1 VIH
K1 Adulto
K1 Hepacivirus
K1 Infecciones por VIH
K1 Hepatitis C crónica
K1 Humanos
K1 Masculino
K1 Mediana edad
K1 Oligopéptidos
K1 Prolina
K1 Rivavirina
K1 Resultado del tratamiento
AB BACKGROUND AND AIMSClinical trials of therapy against chronic hepatitis C virus (HCV) infection including boceprevir (BOC) or telaprevir (TVR) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than those achieved with PR alone. This study sought to evaluate the efficacy and safety of triple therapy including BOC or TVR in combination with PR in HIV/HCV-coinfected patients under real-life conditions.METHODSIn a multicentre study conducted in 24 sites throughout five European countries, all HIV/HCV-coinfected patients who initiated a combination of BOC or TVR plus PR and who had at least 60 weeks of follow-up, were analyzed. Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated.RESULTSOf the 159 subjects included, 127 (79.9%) were male, 45 (34.4%) were treatment-naïve for PR and 60 (45.4%) showed cirrhosis. SVR12 was observed in 31/46 (67.4%) patients treated with BOC and 69/113 (61.1%) patients treated with TVR. Overall discontinuations due to AE rates were 8.7% for BOC and 8% for TVR. Grade 3 or 4 hematological abnormalities were frequently observed; anemia 7%, thrombocytopenia 17.2% and neutropenia 16.4%.CONCLUSIONThe efficacy and safety of triple therapy including BOC or TVR plus PR under real-life conditions of use in the HIV/HCV-coinfected population was similar to what is observed in clinical trials. Hematological side effects are frequent but manageable.
PB Public Libray of Science
YR 2015
FD 2015-04-29
LK http://hdl.handle.net/10668/2407
UL http://hdl.handle.net/10668/2407
LA en
NO Neukam K, Munteanu DI, Rivero-Juárez A, Lutz T, Fehr J, Mandorfer M, et al. Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. PLoS ONE. 2015; 10(4):e0125080
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 8, 2025